Recombinant activated factor VII in cardiac surgery – first, do no harm
نویسندگان
چکیده
منابع مشابه
Recombinant activated factor VII in cardiac surgery – first, do no harm
Letter to the editor We read with interest Heise et al's case report and review of the literature regarding the use of recombinant activated factor VII (rFVIIa) in patients with ventricular assist devices (VAD) [1]. Whilst we welcome the addition to the literature in this area, there are two key areas regarding this relatively novel haemostatic agent that we felt the authors had failed to addre...
متن کاملThe role of recombinant activated factor VII in cardiac surgery
Recombinant factor VIIa may reduce surgical blood loss and transfusion of blood products in cardiac surgery. However, the true risks of its use in this setting remains to be elucidated, especially when it is administered with other potent pro-haemostatic agents. We reviewed the recent literature on this topic and suggest that the off label use of recombinant factor VIIa is likely to continue. I...
متن کاملFactor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.
OBJECTIVE Postcardiopulmonary bypass hemorrhage remains a serious complication of cardiac surgery. Given concerns regarding adverse effects of blood product transfusion and limited efficacy of current antifibrinolytics, procoagulant medications, including recombinant factor VIIa (rFVIIa) and factor eight inhibitor bypass activity (FEIBA), increasingly have been used in managing refractory bleed...
متن کاملFirst, do no harm
Conservation agencies charged with care of threatened plant species should be governed by the concepts that conservation actions should do no harm. Adaptive management research progresses in imperfect situations due to incomplete knowledge. Interpreting new experimental or observational evidence for inclusion in conservation plans should first consider the big picture by identifying collateral ...
متن کاملFirst, do no harm.
Accessible online at: www.karger.com/onk Fax +49 761 4 52 07 14 [email protected] www.karger.com vational study, Pinder et al. report a 26% increased risk of CHF in older women treated with adjuvant anthracyclines for breast cancer, compared with non-anthracycline regimens [8]. Cardiac troponins are regulatory proteins that control the calcium-mediated interaction of actin and myosin. The t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cardiothoracic Surgery
سال: 2007
ISSN: 1749-8090
DOI: 10.1186/1749-8090-2-50